Abdominal Aortic Aneurysm Clinical Trial
— Global FACTOfficial title:
A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair Using the Fenestrated Anaconda™ Device
Verified date | June 2023 |
Source | Vascutek Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a prospective non-interventional, multi-centre study of the Vascutek Fenestrated Anaconda™ system, and is essentially a post-market study. The Vascutek Fenestrated Anaconda™ system is a custom made device used for the treatment of Abdominal Aortic Aneurysm.
Status | Active, not recruiting |
Enrollment | 160 |
Est. completion date | December 31, 2030 |
Est. primary completion date | March 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patients must meet all of the criteria below in order to be eligible for inclusion in the study - 1. Patient is aged 18 years or over on the date of consent 2. Patient is willing and able to comply with all study procedures and study follow-up visits 3. Patient is willing and able to give written informed consent to participate in study 4. Patient has a juxtrarenal or suprarenal abdominal aortic aneurysm (AAA) with maximum sac diameter = 5.5cm, or an AAA = 4.5 cm which has increased by > 1.0 cm in the past year 5. Patient is anatomically suitable for a bifurcated Fenestrated Anaconda™ device NOTE: Both the treating Investigator and the Manufacturer must agree that the proposed patient's anatomy is suitable for treatment using the Fenestrated Anaconda™ device. Where the Investigator proposes that the patient anatomy is suitable and the Manufacturer subsequently disagrees, the patient will be recorded as a screen failure and deemed not eligible for the study. Exclusion Criteria: Any patient who meets any of the criteria below will be excluded from participation in the study - 1. Patient has a life expectancy < 2 years, as judged by the Investigator 2. Patient has psychiatric or other condition that in the opinion of the Investigator may limit their ability to comply with study procedures 3. Patient is participating in another clinical study which in the opinion of the Investigator could influence the outcomes of this study 4. Patient has a known allergy to any device component (polyester, nitinol, nickel) 5. Patient has a coagulopathy or uncontrolled bleeding disorder 6. Patient has a ruptured, leaking or mycotic aneurysm 7. Patient has a serum creatinine (S-Cr) level > 2.0 mg/dL (177 µmol/L) 8. Patient has had CVA or MI within three months of enrolment or treatment 9. Patient has a connective tissue disease (e.g. Marfan Syndrome) 10. Patient has had a previously inserted endovascular stent in the abdominal aorta 11. Patient is pregnant (female of childbearing potential only) |
Country | Name | City | State |
---|---|---|---|
Australia | Epworth Richmond Private Hospital | Melbourne | Victoria |
Australia | Hollywood Medical Centre | Perth | Western Australia |
Austria | Wilhelminenspital | Vienna | |
Canada | Peter Lougheed Centre | Calgary | Alberta |
Netherlands | Rijnstate Hospital | Arnhem | |
Netherlands | Medisch Spectrum Twente (MST) | Enschede | |
Netherlands | Universitair Medisch Centrum Groningen (UMCG) | Groningen | |
Netherlands | Antonius Ziekenhuis | Nieuwegein | |
United Kingdom | Frimley Park Hospital | Camberley | |
United Kingdom | Imperial College, St Mary's Hospital | London | |
United Kingdom | Freeman Hospital | Newcastle upon Tyne | Tyne And Wear |
Lead Sponsor | Collaborator |
---|---|
Vascutek Ltd. |
Australia, Austria, Canada, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients who experience Treatment Success. | Treatment success is defined as freedom from the following: Type I and III endoleak; stent graft migration; AAA enlargement; AAA rupture; conversion to open surgery; non-patent endoluminal grafts and/or significant twists, kinks or obstruction; aneurysm-related patient death. | 1 year post-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04227054 -
Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks
|
N/A | |
Active, not recruiting |
NCT03687489 -
Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System
|
N/A | |
Active, not recruiting |
NCT03507413 -
Metformin Therapy in Non-diabetic AAA Patients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05756283 -
The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair
|
N/A | |
Not yet recruiting |
NCT04089241 -
Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair
|
N/A | |
Active, not recruiting |
NCT02604303 -
A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
|
||
Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
Completed |
NCT02224794 -
LIFE Study: Least Invasive Fast-Track EVAR
|
||
Terminated |
NCT01843335 -
Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair
|
N/A | |
Completed |
NCT02229006 -
Sodium Fluoride Imaging of Abdominal Aortic Aneurysms
|
N/A | |
Terminated |
NCT01425242 -
Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension
|
N/A | |
Completed |
NCT01118520 -
AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
|
Phase 2 | |
Completed |
NCT00746122 -
Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair
|
N/A | |
Completed |
NCT03952780 -
Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
|
||
Completed |
NCT00583414 -
Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
|
N/A | |
Recruiting |
NCT05864560 -
Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
|
||
Completed |
NCT01683084 -
Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
|
Phase 4 | |
Completed |
NCT02493296 -
The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
|
||
Completed |
NCT03320408 -
Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers
|
||
Completed |
NCT03837704 -
Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.
|
N/A |